Navigation Links
Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
Date:1/7/2014

REDWOOD CITY, Kalifornien, 7. Januar 2014 /PRNewswire/ -- Denny Lanfear, der Präsident und CEO von Coherus Biosciences, wird bei der 32. J.P. Morgan Annual Healthcare Conference, am Mittwoch, den 15. Januar ab 16:30 Uhr (Pacific Standard Time) im Hotel Westin St. Francis in San Francisco, Kalifornien, einen Vortrag halten.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

„Die geplante Präsentation bei dieser Konferenz stellt einen bedeutenden Meilenstein für Coherus dar. Bei dieser Veranstaltung hat Coherus Biosciences die Gelegenheit, sich einem Publikum aus internationalen Investoren im Gesundheitsbereich vorzustellen und zu zeigen, welche großen Fortschritte das Unternehmen bei seinen Produkten und Partnerschaften erzielt hat", erklärt Lanfear. „Zurzeit hat Coherus für drei Produkte den IND-Status beantragt und Partnerschaftsverträge mit großen Biopharmaunternehmen in Asien, Lateinamerika und Europa geschlossen. Die US-Rechte an sämtlichen Produkten bleiben jedoch im Unternehmen. Wir glauben, dass Coherus sich durch diese Fortschritte als führendes unabhängiges Unternehmen, das sich ausschließlich auf Biosimilars spezialisiert hat, etablieren konnte."

Informationen zu Coherus Biosciences

Coherus Biosciences wurde 2010 gegründet und hat sich ausschließlich auf Biosimilars spezialisiert. In dieser Sparte ist das in der San Francisco Bay Area ansässige Unternehmen führend. Biosimilars sollen anstelle von vorhandenen biologischen Markenpräparaten bei der Behandlung unterschiedlicher chronischer und oft lebensbedrohlicher Erkrankungen eingesetzt werden. Wir haben es uns zur Aufgabe gemacht, weltweit mehr Patienten den Zugang zu hochwertigen, leb
'/>"/>

SOURCE Coherus BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
2. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
3. Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
4. Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
5. Senhwa Biosciences Raises $17M Series B
6. Merriman Capital to Host Pressure BioSciences, Inc. Investor Call at 4:30 p.m. EST on Thursday, December 12, 2013
7. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
8. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
9. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
10. 3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
11. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Dayton, Ohio (PRWEB) August 22, 2014 Dayton ... patient care tower as part of a $141 million campus ... new patient care tower were unveiled to the public. ... campus facilities plan that will create a campus that meets ... the future. These new care spaces will embody Dayton Children’s ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
(Date:8/22/2014)... News) -- Many children get anxious or afraid when ... a number of ways that parents can make these ... The first step is to explain to children in ... health, said Rita John, director of the pediatric primary ... Nursing in New York City. "Children need to ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2
... could ease sickle-cell disease and thalassemia , ... ... Hospital Boston ( www.childrenshospital.org ) and Dana-Farber Cancer Institute have ... a form of hemoglobin normally made only before birth or ...
... Toy Safety Program Offers Manufacturers A Way to Improve Toy ... Improvement Act , , ANN ... generate concerns among consumers about the safety of their children,s ... Safety team offers a solution -- integrated services that include ...
... 4 Omron Healthcare, Inc. reminds,consumers to take full ... (FSA,s) before they expire by purchasing products to take,control ... blood pressure,monitors and nebulizers. , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-b ...
... Nash Corporation (Nasdaq: KNSY ) is scheduled to participate ... 2008 RBC Capital Markets Healthcare Conference. , , ... the panel discussion on Thursday, December 11th at 11:00 a.m. ET ... The conference is by invitation only, however individuals can listen ...
... of vigorous activity a week , , THURSDAY, Dec. 4 ... in the United States last year met the 2008 ... those people met the Healthy People 2010 physical activity ... , According to the 2008 guidelines, released in October ...
... family today unveiled,the details of a successful holiday party held ... possible by Biel,s Make The Difference,Network, included numerous recording artists ... spirit to children at the hospital. , ... well as seeing some of the,great artists we had at ...
Cached Medicine News:Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:NSF International Offers Answers to Rising Toy Safety Concerns 2Health News:Maximize Flex Spending Account Funds Before They Expire 2Health News:Maximize Flex Spending Account Funds Before They Expire 3Health News:Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2
The Heine C series binocular loupes offer extremely low weight (46 g), crisp views, and quality German construction in an affordable instrument....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Easyloupes are exceptional optics that you have come to expect from Oculus. Available in either 1.8x or 2.5x magnification and 40 cm working distance (15.75 inches), they have the well-known durabili...
... implant is a device that delivers ... Cytomegalovirus (CMV) Retinitis. This approach can ... compared with conventional intravenous treatment. The ... a polymer-based system that slowly releases ...
Medicine Products: